Michael A Fridrik
Michael A Fridrik
s concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed. ...
Novel concepts of antiangiogenic therapies in metastatic renal cell cancer [0.03%]
转移性肾细胞癌抗血管生成疗法的新概念
Renate Pichler,Isabel Heidegger
Renate Pichler
The era of antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway has become a mainstay in the treatment of metastatic renal cell carcinoma (mRCC), showing primary responses in 65-70% of patients. Nev...
Antiangiogenic therapies in urogenital malignancies: Fiction or fact? [0.03%]
抗血管生成疗法治疗泌尿生殖系肿瘤：是真是幻？
Friederike Haidl,David Pfister,Axel Heidenreich et al.
Friederike Haidl et al.
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic rena...
Simon Peter Gampenrieder,Theresa Westphal,Richard Greil
Simon Peter Gampenrieder
Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported...
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update [0.03%]
治疗血管肉瘤的抗血管生成疗法：临床更新
Robin J Young,Penella J Woll
Robin J Young
Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have r...
Ruth Exner
Ruth Exner
During the San Antonio Breast Cancer Symposium in December 2016, the main topics were systemic treatment of breast cancer and molecular research. But several studies were also presented concerning local therapy: Surgical issues on evaluatin...
Pascal A T Baltzer,Panagiotis Kapetas,Maria Adele Marino et al.
Pascal A T Baltzer et al.
Imaging plays a major role in the diagnosis, treatment, and follow-up of breast cancer. Findings that require further assessment will be detected both at screening and curative mammography. Most findings that are further worked up tend to y...
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer [0.03%]
转移性胰腺癌的交叉对比和新的化疗方案
Markus Kieler,Matthias Unseld,Daniela Bianconi et al.
Markus Kieler et al.
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4-5%. Indeed, long-term survival was not affected by the introductio...
Klaus Kaczirek
Klaus Kaczirek
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three c...
Simon Peter Gampenrieder,Gabriel Rinnerthaler,Richard Greil
Simon Peter Gampenrieder
At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of ful...